BiotechTube

Tilmanocept

Phase 1Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 11/100
11
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Arthritis, Rheumatoid

Conditions

Arthritis, Rheumatoid

Trial Timeline

Sep 1, 2017 → Mar 1, 2018

NCT ID
NCT03241446

About Tilmanocept

Tilmanocept is a phase 1 stage product being developed by Navidea Biopharmaceuticals for Arthritis, Rheumatoid. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03241446. Target conditions include Arthritis, Rheumatoid.

What happened to similar drugs?

20 of 20 similar drugs in Arthritis, Rheumatoid were approved

Approved (20) Terminated (0) Active (0)
✅NISEDr. Reddy's LaboratoriesApproved
✅Duloxetine + Sugar pillEli LillyApproved
✅Baricitinib + TNF InhibitorEli LillyApproved
✅Ixekizumab + AdalimumabEli LillyApproved
✅TacrolimusAstellas PharmaApproved
✅tacrolimus + methotrexate + adalimumab + tocilizumab + abataceptAstellas PharmaApproved
✅tacrolimus + placeboAstellas PharmaApproved

Hype Score Breakdown

Clinical
6
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT03241446Phase 1Withdrawn
NCT02683421Phase 1Completed

Competing Products

20 competing products in Arthritis, Rheumatoid

See all competitors
ProductCompanyStageHype Score
DRL_RI + Rituxan + MabTheraDr. Reddy's LaboratoriesPhase 1/2
29
Experimental: Arm A: DRL_RI + Arm B: Rituxan®/Mabthera®Dr. Reddy's LaboratoriesPhase 3
37
NISEDr. Reddy's LaboratoriesApproved
40
NISELATDr. Reddy's LaboratoriesPre-clinical
23
Test Product + Reference product + Reference Medicinal ProductDr. Reddy's LaboratoriesPhase 1
22
Tocilizumab Prefilled SyringeDr. Reddy's LaboratoriesPhase 1
26
Tc99m tilmanoceptNavidea BiopharmaceuticalsPhase 2
25
KPL-404 + PlaceboKiniksa PharmaceuticalsPhase 2
29
Baricitinib + Methotrexate + Baricitinib Placebo + MTX Placebo + Folic AcidEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
LY2828360 + PlaceboEli LillyPhase 2
35
Investigational Medical Product (IMP) administered in parent studyEli LillyPhase 3
40
SonelokimabMoonLake ImmunotherapeuticsPhase 3
41
Sonelokimab + Placebo + AdalimumabMoonLake ImmunotherapeuticsPhase 2
29
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
38
Sonelokimab + Placebo + RisankizumabMoonLake ImmunotherapeuticsPhase 3
41
Dose A VTX958 + Dose B VTX958 + PlaceboVentyx BiosciencesPhase 2
21
LY2127399Eli LillyPhase 3
32
Ixekizumab + PlaceboEli LillyPhase 3
40
Duloxetine + Sugar pillEli LillyApproved
43